Kathleen N. Moore
YOU?
Author Swipe
View article: Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancer
Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancer Open
Purpose:Low-grade serous ovarian carcinoma(LGSOC) is a distinct form of ovarian cancer characterised by younger patient age and relative chemoresistance. The GOG281/LOGS trial(NCT02101788) investigated the efficacy of the MEK inhibitor tra…
View article: Supplementary Materials from First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
Supplementary Materials from First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma Open
Supplementary Tables and Figures
View article: Supplementary Figure S3 from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
Supplementary Figure S3 from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial Open
PFS according to homologous recombination and BRCA1/2 status in the subgroup of patients with IC ≥5%.
View article: Supplementary Figure S4 from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
Supplementary Figure S4 from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial Open
PFS by treatment arm according to TMB status (stratified by treatment approach, disease stage, and ECOG PS). A, TMB-low population. B, TMB-high population. CPB, paclitaxel, carboplatin, and bevacizumab.
View article: Modified Balloon-Assisted Thrombin Injection via Distal Access for Complex Femoral Pseudoaneurysms
Modified Balloon-Assisted Thrombin Injection via Distal Access for Complex Femoral Pseudoaneurysms Open
View article: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201 Open
PURPOSE This study evaluated the efficacy and safety of avutometinib (rapidly accelerated fibrosarcoma/mitogen-activated extracellular signal-regulated kinase [MEK] clamp) alone or in combination with defactinib (focal adhesion kinase inhi…
View article: Supplementary Figure S2 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Supplementary Figure S2 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial Open
Supplementary Figure 2. Hazard Ratio estimates in subgroup analysis based on the stratification factors. Hazard ratios (HR) are estimated with a proportional hazards model stratified by prior exposure to PARP inhibitor (PARPi) (yes vs no) …
View article: Supplementary Table S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Supplementary Table S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial Open
Supplementary Table 1. Baseline Patient Characteristics
View article: Supplementary Table S3 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Supplementary Table S3 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial Open
Supplementary Table 3. Experimental Arm Hazard Ratio Estimates for interim analysis (N = 120)
View article: Supplementary Table S2 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Supplementary Table S2 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial Open
Supplementary Table 2: Representativeness of Study Participants
View article: Supplementary Figure S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Supplementary Figure S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial Open
Supplementary Figure 1. Progression-free survival and overall survival by randomized treatment (N = 120). Distributions were estimated utilizing the Kaplan-Meier method for progression-free survival (PFS) by investigator assessment. Hazard…
View article: Supplementary Appendix S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Supplementary Appendix S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial Open
Appendix
View article: Data from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Data from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial Open
Purpose:We assessed the efficacy of anti–PD-L1 durvalumab in combination with olaparib and cediranib (DOC), compared with the standard-of-care chemotherapy (SOC) in patients with platinum-resistant ovarian cancer (PROC), who had prior beva…
View article: Expanding the workforce of clinical trial investigators committed to gynecologic cancer research: the GOG Foundation, Inc’s Scholar Career Development Award and New Investigator Program
Expanding the workforce of clinical trial investigators committed to gynecologic cancer research: the GOG Foundation, Inc’s Scholar Career Development Award and New Investigator Program Open
The GOG-F Scholar Career Development Award has demonstrated strong success in cultivating clinical trial leaders through structured mentorship and protected research time. The New Investigator Program has effectively fostered early-career …
View article: 45P Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without olaparib as first-line treatment for endometrial cancer: Progression-free survival and safety by age above/below 70 years and with/without clinical obesity in the DUO-E trial
45P Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without olaparib as first-line treatment for endometrial cancer: Progression-free survival and safety by age above/below 70 years and with/without clinical obesity in the DUO-E trial Open
View article: Correction: Health disparities in cervical cancer: Estimating geographic variations of disease burden and association with key socioeconomic and demographic factors in the US
Correction: Health disparities in cervical cancer: Estimating geographic variations of disease burden and association with key socioeconomic and demographic factors in the US Open
[This corrects the article DOI: 10.1371/journal.pone.0307282.].
View article: Long-Term Survival in Patients With Low-Risk Cervical Cancer After Simple, Modified, or Radical Hysterectomy
Long-Term Survival in Patients With Low-Risk Cervical Cancer After Simple, Modified, or Radical Hysterectomy Open
Importance Three-year pelvic recurrence rate in women with low-risk cervical carcinoma was not inferior following simple hysterectomy (SH) vs modified radical hysterectomy (MRH) or radical hysterectomy (RH) in the Simple Hysterectomy and P…
View article: The promise and translation of cell-free human papillomavirus DNA testing for cervical cancer surveillance
The promise and translation of cell-free human papillomavirus DNA testing for cervical cancer surveillance Open
View article: The dynamic immune behavior of primary and metastatic ovarian carcinoma
The dynamic immune behavior of primary and metastatic ovarian carcinoma Open
View article: Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial
Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial Open
The poor prognostic OC patient subgroup, may have an extension of PFS from treatment intensification with atezolizumab added to frontline chemotherapy-bevacizumab regimen. This hypothesis-generating outcome warrants further understanding o…
View article: Mepitel Film Versus <scp>StrataXRT</scp> in Managing Radiation Dermatitis in an Intra‐Patient Controlled Clinical Trial of 80 Postmastectomy Patients
Mepitel Film Versus <span>StrataXRT</span> in Managing Radiation Dermatitis in an Intra‐Patient Controlled Clinical Trial of 80 Postmastectomy Patients Open
Background Mepitel film decreases the severity of radiation dermatitis in breast cancer patients, but its application is resource‐intensive. Many departments therefore use StrataXRT, a gel that patients apply themselves. We compared the pr…
View article: Marine Mammal Stranding Networks in the 21st Century: Whence and Whither?
Marine Mammal Stranding Networks in the 21st Century: Whence and Whither? Open
View article: Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugates
Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugates Open
Background The surrogacy of overall response rate (ORR) or progression-free survival (PFS) for overall survival (OS) at the trial-level in randomized clinical trials (RCTs) testing antibody-drugs conjugates (ADC) has never been investigate…
View article: Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study
Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study Open
PURPOSE Approximately 50% of patients with advanced Merkel cell carcinoma (MCC) have primary or acquired resistance to PD-(L)1 blockade, which may be overcome using combination immune checkpoint inhibition (ICI) with anti–cytotoxic T lymph…
View article: Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update Open
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Gui…
View article: A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors
A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors Open
Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors, such as olaparib, talazoparib, rucaparib, and niraparib, comprise a therapeutic class that targets PARP proteins involved in DNA repair. Cancer cells with homologous recombin…
View article: Benefit from the Immune Checkpoint Inhibitor Atezolizumab Addition in Poor Prognostic Ovarian Cancer Patients : Imagyn050 Trial
Benefit from the Immune Checkpoint Inhibitor Atezolizumab Addition in Poor Prognostic Ovarian Cancer Patients : Imagyn050 Trial Open
View article: High voltinism, late-emerging butterflies are sensitive to interannual variation in spring temperature in North Carolina
High voltinism, late-emerging butterflies are sensitive to interannual variation in spring temperature in North Carolina Open
Climate change has been repeatedly linked to phenological shifts in many taxa, but the factors that drive variation in phenological sensitivity remain unclear. For example, relatively little is known about phenological responses in areas t…
View article: Symptom trajectories over time by cannabis use status among patients undergoing cancer treatment
Symptom trajectories over time by cannabis use status among patients undergoing cancer treatment Open
Adults with cancer may perceive cannabis as beneficial for managing their cancer-related symptoms, but the evidence supporting its medical use is varied and inconclusive. This study characterized associations of cannabis use with cancer-re…
View article: High voltinism, late-emerging butterflies are sensitive to interannual variation in spring temperature in North Carolina
High voltinism, late-emerging butterflies are sensitive to interannual variation in spring temperature in North Carolina Open
Climate change has been repeatedly linked to phenological shifts in many taxa, but the factors that drive variation in phenological sensitivity remain unclear. For example, relatively little is known about phenological responses in areas t…